Prostate Cancer Theranostics: PSMA Targeted Therapy

Robert Seifert; Ian L Alberts; Ali Afshar-Oromieh; Kambiz Rahbar

doi:10.1016/j.cpet.2021.03.004

Prostate Cancer Theranostics: PSMA Targeted Therapy

PET Clin. 2021 Jul;16(3):391-396. doi: 10.1016/j.cpet.2021.03.004.

Authors

Robert Seifert¹, Ian L Alberts², Ali Afshar-Oromieh², Kambiz Rahbar³

Affiliations

¹ Department of Nuclear Medicine, University Hospital Münster, Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; West German Cancer Center (WTZ); German Cancer Consortium (DKTK).
² Department of Nuclear Medicine, University Hospital, Inselspital Bern, Bern, Switzerland.
³ Department of Nuclear Medicine, University Hospital Münster, Münster, Germany; West German Cancer Center (WTZ). Electronic address: rahbar@uni-muenster.de.

PMID: 34053583
DOI: 10.1016/j.cpet.2021.03.004

Abstract

Prostate-specific membrane antigen (PSMA) has been the subject of numerous studies within the last 3 decades. PSMA-targeted imaging and therapy have significantly changed the management of patients with prostate cancer in various disease stages, especially in advanced metastasized castration-resistant prostate cancer. Lutetium-177-conjugated PSMA-617 or PSMA-I&T (Lu-PSMA) has shown promising results in multicenter retrospective and monocenter prospective trials. The aim of this review is to provide an overview of the history and current and future developments of PSMA-targeted therapy. A special focus of this review is on PSMA PET-guided management of patients receiving PSMA-targeted radioligand therapy.

Keywords: PSMA; Prostate cancer; Prostate-specific membrane antigen; Theranostics.

Publication types

Review

MeSH terms

Humans
Male
Multicenter Studies as Topic
Precision Medicine
Prospective Studies
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / therapy
Prostatic Neoplasms, Castration-Resistant* / diagnostic imaging
Retrospective Studies
Theranostic Nanomedicine